For example, response rates to single-agent PD-1/PD-L1 inhibition in unselected patients with melanoma, NSCLC, and RCC are 40% (7, 8), 25% (8, 9), and 19% (10), respectively (11). The gene discussed is CD274; the disease is melanoma.